Genus's First Buyback Is the Tell: PRP Promise Finally Turns Into Cash

FY26 profit +35% and a maiden £60m return — but the China JV and a Latin American PRP launch show the business is quietly changing shape.

GNS.L · Earnings Call · 2026-09-10

A first: surplus capital actually returned

Genus has spent years pitching two "potentially transformative" engines — a PRRS-resistant pig and China — while pouring cash into R&D. FY2026 is the year those stories crossed from promise into balance-sheet fact. Adjusted profit before tax rose 35% to £100.2m, free cash flow reached £62m, leverage fell from 1.5x to 0.4x, and management announced its maiden buyback.

In line with our capital allocation framework, we are therefore announcing a £60 million share buyback which we expect to be completed in FY 2027. The buyback reflects the Group's strong balance sheet, strong sustainable cash generation, and the board's confidence in the future growth prospects of the business. I am also pleased to report that the board is recommending a 10% increase in the full year dividend.
Jorgen Kokke, Chief Executive Officer · 2026-09-10

The buyback itself is the news. Andy Russell was candid about the calibration: “this is our first buyback that we have done. And so I want to be cautious.” — Andrew Paul Russell, Chief Financial Officer · 2026-09-10 At £60m against roughly £81m of net JV proceeds, post-buyback leverage still lands near the bottom of the 1–2x target range — deliberate strategic optionality preserved.

The joint venture as a value-crystallisation engine

The biggest structural change is the China deal. The joint venture did two things at once: it deconsolidated PIC China (group revenue fell 2% in actual currency), and it threw off a £204m statutory deconsolidation gain — the reason statutory PBT ballooned to £310.5m while adjusted PBT is the cleaner read. Andy walked analysts through a careful normalisation to a £90.3m pro-forma base as the right launch point for FY27. The Royalty revenue line — now pitched as the metric that best captures JV contribution — reached £197m adjusted, a ~6% four-year CAGR with joint ventures themselves compounding at 12%. And Jorgen flagged the real prize:

We estimate that PIC's market share increased from 3.4% in FY 2025 to 5.4% in FY 26. This demonstrates that customers continue to recognize the economic value of our genetics even in a challenging market.
Jorgen Kokke, Chief Executive Officer · 2026-09-10

That is a Southeast Asia-plus-China engine gaining two points of share in the world's largest porcine market even as pork prices weaken — the classic "in bad times customers go to PIC for productivity" dynamic Jorgen leaned on. Meanwhile the BCA milestone receipt (£5.6m) has become a recurring footnote that muddies year-on-year comparisons; it drops out of FY27 entirely.

PRP stops being a slide and starts being a sale

For years PRP was a regulatory waiting game — Mexico, Japan, China perpetually "in process." The change this quarter is that commercialisation has actually begun. “Commercialization is beginning in selected Latin American countries. Our goal is to establish operational and customer foundations, for long term adoption.” — Jorgen Kokke, Chief Executive Officer · 2026-09-10 Peru is the named first market, with terms in line with the Capital Markets Day guideposts. The China regulatory angle is arguably the more valuable one: “China is the only country where we had to do local disease challenge studies... we did more testing in China than we did in the US.” — Jorgen Kokke, Chief Executive Officer · 2026-09-10 That work is now complete; a dossier submission is the next step, with the BCA partner's government connectivity as a tailwind.

What's absent — and the ABS grind

Contrast with the prior call. Back in February 2025 the very first analyst question was about tariffs: “can you just talk a little bit about tariffs and what you see in both PIC and ABS?” — Charles Hall, Analyst · 2025-02-28 This quarter: nothing. That is striking given how dominant tariff-refund mechanics are across the broader market right now — Tariff Refund benefits were cited by AEO, ASO, DBI, JILL, M and VNCE in the same reporting window. Genus is a rare name that sits this cycle out entirely. The unfinished business is ABS, still grinding toward a double-digit margin — now 7.5% from 6.3%. Jorgen framed the VAP successor as commercial excellence plus operational excellence. Note how far the ambition has drifted: in 2023 management spoke of an “aspirational goal of 20% margin” — Seb Jantet, Analyst · 2023-09-07 for ABS; today the target is only "double digit over the medium term." The competitive backdrop adds intrigue — an ST/Select merger Jorgen declined to handicap beyond “there are certainly rumors out there.” — Andrew Paul Russell, Chief Financial Officer · 2026-09-10

The takeaway

FY27 guidance is deliberately soft: "moderately higher" underlying PBT, second-half weighted, with Brazil breeding-stock sales rolling over and North American PRRS-driven volume weakness persisting into H1. But the composition of the story has changed. A cash-generative business returning capital for the first time, a China platform now partly owned rather than wholly consolidated, and a gene-edited product generating real-world commercial data. Genus is in the middle of transitioning from an investment story to a cash story — and the market has barely been given a tape to price it against.